Cigna Investments Inc. New lifted its position in shares of Humana Inc (NYSE:HUM) by 102.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,298 shares of the insurance provider’s stock after purchasing an additional 3,701 shares during the period. Cigna Investments Inc. New’s holdings in Humana were worth $2,292,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Allied Advisory Services Inc. increased its position in shares of Humana by 3.7% during the fourth quarter. First Allied Advisory Services Inc. now owns 6,284 shares of the insurance provider’s stock worth $2,305,000 after purchasing an additional 223 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Humana by 135.5% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 664 shares of the insurance provider’s stock worth $243,000 after purchasing an additional 382 shares in the last quarter. World Asset Management Inc increased its position in shares of Humana by 0.5% during the fourth quarter. World Asset Management Inc now owns 10,827 shares of the insurance provider’s stock worth $3,968,000 after purchasing an additional 59 shares in the last quarter. IBM Retirement Fund increased its position in Humana by 51.0% in the 1st quarter. IBM Retirement Fund now owns 3,493 shares of the insurance provider’s stock valued at $1,097,000 after acquiring an additional 1,179 shares during the period. Finally, Tobam increased its position in Humana by 10.9% in the 4th quarter. Tobam now owns 79,083 shares of the insurance provider’s stock valued at $28,986,000 after acquiring an additional 7,755 shares during the period. Institutional investors and hedge funds own 93.22% of the company’s stock.
Shares of NYSE:HUM traded down $0.84 during trading on Friday, hitting $394.43. 415,854 shares of the stock were exchanged, compared to its average volume of 962,079. Humana Inc has a 12-month low of $208.25 and a 12-month high of $412.70. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.49. The company has a fifty day moving average price of $361.93 and a two-hundred day moving average price of $345.82. The company has a market cap of $52.26 billion, a PE ratio of 20.25, a P/E/G ratio of 1.73 and a beta of 0.91.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.84 by $0.56. Humana had a return on equity of 21.02% and a net margin of 3.86%. The firm had revenue of $18.94 billion for the quarter, compared to analyst estimates of $18.49 billion. During the same quarter in the prior year, the company earned $4.48 EPS. Humana’s revenue was up 17.6% on a year-over-year basis. Equities research analysts anticipate that Humana Inc will post 18.55 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.625 dividend. This represents a $2.50 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Monday, June 29th. Humana’s payout ratio is currently 13.99%.
Several equities analysts recently issued reports on the company. Citigroup boosted their price target on Humana from $424.00 to $435.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Cantor Fitzgerald boosted their price target on Humana from $345.00 to $400.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Morgan Stanley boosted their price target on Humana from $375.00 to $500.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating and set a $396.00 price objective on the stock. in a report on Friday, April 17th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $370.00 price objective on shares of Humana in a report on Wednesday, February 19th. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $405.42.
In other Humana news, Director David A. Jr/Ky Jones sold 5,800 shares of the business’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $256.19, for a total value of $1,485,902.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.42% of the company’s stock.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Stock Market – What is a circuit breaker?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.